Regulatory Filings • Jun 23, 2020
Regulatory Filings
Open in ViewerOpens in native device viewer
BerGenBio to Present at the Upcoming Virtual European Biotech Investor Day 2020
Bergen, Norway, June 23, 2020 - BerGenBio, a clinical-stage biopharmaceutical
company developing novel, selective AXL kinase inhibitors for multiple cancer
indications today announces that Richard Godfrey, CEO plans to present an
overview of the Company at the upcoming Virtual European Biotech Investor Day
2020 (https://troutaccess.com/investor.php/con/12490/1547/European+Biotech+Invest
or+Day+2020.html) hosted by Solebury Trout, Goodwin, Deutsche Bank and Nasdaq.
During the 30 minute presentation, participants will be able to submit questions
electronically with answers provided at the discretion of the Company on an
individual basis afterwards.
Date and time: Thursday June 25, at 1:00 p.m. EDT (7:00 p.m. CET).
View and attend the event online: www.webcaster4.com/Webcast/Page/2408/35370
The presentation will also be made available on the Company's website after the
event has ended on 25 June at www.bergenbio.com/investors/presentations/
- END -
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company's proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II oncology clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is
developing companion diagnostic tests to identify patient populations most
likely to benefit from bemcentinib: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com
About AXL
AXL kinase is a cell membrane receptor and an essential mediator of the
biological mechanisms underlying life-threatening diseases. In cancer, AXL
suppresses the body's immune response to tumours and drives cancer treatment
failure across many indications. AXL expression defines a very poor prognosis
subgroup in most cancers. AXL inhibitors, therefore, have potential high value
at the centre of cancer combination therapy, addressing significant unmet
medical needs and multiple high-value market opportunities. Research has also
shown that AXL mediates other aggressive diseases.
About Bemcentinib
Bemcentinib (formerly known as BGB324), is a potentially first-in-class
selective AXL inhibitor in a broad phase II clinical development programme.
Ongoing clinical trials are investigating bemcentinib in multiple solid and
haematological tumours, in combination with current and emerging therapies
(including immunotherapies, targeted therapies and chemotherapy), and as a
single agent. Bemcentinib targets and binds to the intracellular catalytic
kinase domain of AXL receptor tyrosine kinase and inhibits its activity.
Increase in AXL function has been linked to key mechanisms of drug resistance
and immune escape by tumour cells, leading to aggressive metastatic cancers.
Contacts
Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304
Rune Skeie, CFO, BerGenBio ASA
+47 917 86 513
International Media Relations
Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs
Consilium Strategic Communications
+44 20 3709 5700
Media Relations in Norway
Jan Petter Stiff, Crux Advisers
+47 995 13 891
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.